(Q36134870)

English

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 August 2017

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients (English)

1 reference

Europe PubMed Central

12 August 2017

1 reference

based on heuristic

inferred from title

author name string

van der Wall E

1

1 reference

Europe PubMed Central

12 August 2017

Rutgers EJ

2

1 reference

Europe PubMed Central

12 August 2017

Holtkamp MJ

3

1 reference

Europe PubMed Central

12 August 2017

Baars JW

4

1 reference

Europe PubMed Central

12 August 2017

Schornagel JH

5

1 reference

Europe PubMed Central

12 August 2017

Peterse JL

6

1 reference

Europe PubMed Central

12 August 2017

Beijnen JH

7

1 reference

Europe PubMed Central

12 August 2017

Rodenhuis S

8

1 reference

Europe PubMed Central

12 August 2017

language of work or name

0 references

publication date

1 May 1996

1 reference

Europe PubMed Central

12 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

12 August 2017

73

1 reference

Europe PubMed Central

12 August 2017

9

1 reference

Europe PubMed Central

12 August 2017

1080-1085

1 reference

Europe PubMed Central

12 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.1996.208

0 references

Drugs ten years later: epirubicin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 October 2017

Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 October 2017

Management of locally advanced carcinoma of the breast. I. Noninflammatory.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 October 2017

High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 October 2017

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 October 2017

Ductal carcinoma in situ (intraductal carcinoma) of the breast

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 October 2017

Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 October 2017

Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 July 2018

Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 July 2018

Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 July 2018

Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 July 2018

Long-term results of a combined modality approach in treating inflammatory carcinoma of the breast

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 July 2018

Neoadjuvant chemotherapy in 126 operable breast cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 July 2018

Primary radiotherapy of breast cancer: treatment results in locally advanced breast cancer and in operable patients selected by positive axillary apex biopsy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 July 2018

Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantion incorporating carboplatin, cyclophosphamide and thiotepa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 July 2018

Systemic therapy combined with radiotherapy for primary inoperable carcinoma of the breast

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074408

2 July 2018

Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8624267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/8624267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CARCINOMA OF THE BREAST: II. CRITERIA OF OPERABILITY

1 reference

https://pubmed.ncbi.nlm.nih.gov/8624267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792)

1 reference

https://pubmed.ncbi.nlm.nih.gov/8624267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8624267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mammography in the assessment of response to medical treatment of large primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8624267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multidisciplinary treatment approach to locally advanced non-inflammatory breast cancer using chemotherapy and radiotherapy with or without surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/8624267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of estrogen receptor assays in human breast cancer tissue

1 reference

https://pubmed.ncbi.nlm.nih.gov/8624267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8624267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/8624267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm

1 reference

https://pubmed.ncbi.nlm.nih.gov/8624267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T3b-T4 breast cancer: factors affecting results in combined modality treatments

1 reference

https://pubmed.ncbi.nlm.nih.gov/8624267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study

1 reference

https://pubmed.ncbi.nlm.nih.gov/8624267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subclavicular biopsy as a guideline for the treatment of breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8624267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/8624267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1996.208

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36134870&oldid=1980597305"